Company profile: Senesco Technologies
1.1 - Company Overview
Company description
- Provider of biotech research and development focused on cancer therapeutics and plant gene research.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Senesco Technologies
OncoPep
HQ: United States
Website
- Description: Provider of investigational multi-peptide therapeutic cancer vaccines and adoptive T cell therapies, including PVX-410 for patients with triple negative breast cancer (TNBC) and asymptomatic multiple myeloma (MM)/smoldering multiple myeloma (SMM); MTAA-420 for multiple myeloma; and second-generation vaccines PVX-024/PVX-510 to enhance the first iteration of OncoPep's vaccine and expand to additional HLA subtypes, such as HLA-A24.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoPep company profile →
Y-mAbs Therapeutics
HQ: United States
Website
- Description: Provider of innovative cancer treatments and support services, including FDA-approved DANYELZA (naxitamab-gqgk) for relapsed or refractory high-risk neuroblastoma in bone or bone marrow; clinical trials for investigational therapies (naxitamab, omburtamab, GD2-SADA); expanded access programs; Y-mAbs Connect for access, insurance and financial support; and patient and family resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Y-mAbs Therapeutics company profile →
Ideaya Biosciences
HQ: United States
Website
- Description: Provider of oncology therapeutics for genetically defined cancers, with clinical-stage programs including darovasertib (IDE196) for GNAQ/GNA11-mutant tumors (metastatic uveal melanoma), IDE397 targeting MAT2A for MTAP-deleted tumors, and IDE161 for HRD tumors. Also offers synthetic lethality target identification with UCSD (CRISPR screens) and biomarker and translational research with the Broad Institute.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ideaya Biosciences company profile →
Dynavax
HQ: United States
Website
- Description: Provider of biopharmaceutical products to prevent infectious diseases, including HEPLISAV-B, an adult hepatitis B vaccine designed to prevent infection by all known subtypes of the virus, and CpG 1018, an adjuvant used in vaccines to enhance the immune response and contained in the HEPLISAV-B hepatitis B vaccine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dynavax company profile →
Opexa Therapeutics
HQ: United States
Website
- Description: Provider of patient-specific immunotherapies for the treatment of multiple sclerosis; its lead candidate, Tcelna, is a personalized T-cell immunotherapy in Phase IIb clinical development (the Abili-T trial).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Opexa Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Senesco Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Senesco Technologies
2.2 - Growth funds investing in similar companies to Senesco Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Senesco Technologies
4.2 - Public trading comparable groups for Senesco Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →